Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31368540 | 1.00 | ALDH1A1 (0.52) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL569249 | 0.88 | ALDH1A1 (0.59) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| Hydrochloric Acid SCHEMBL29890892 | 0.86 | ALDH1A1 (0.57) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL5204247 | 0.86 | KDM4E (0.61) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL29371765 | 0.83 | KDM4E (0.53) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL14479830 | 0.83 | KDM4E (0.53) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL1179728 | 0.82 | CA12 (0.53) | ALDH1A1KDM4EKMT2AMEN1CA12 | |
| SCHEMBL21200349 | 0.81 | KDM4E (0.52) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL29867038 | 0.81 | KDM4E (0.52) | ALDH1A1KDM4EKMT2AHPGDMEN1 | |
| SCHEMBL9288795 | 0.81 | KDM4E (0.55) | ALDH1A1KDM4EKMT2AHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720071-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4622713-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-08-07 | — | — | US | disclosed |
| US-20250223300-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BETTA PHARMACEUTICALS CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| WO-2025109540-A1 | MACROCYCLIC COMPOUNDS AS KIF18A INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-30 | — | — | WO | disclosed |
| EP-4559920-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | ALDH1A1 1935/4885KDM4E 516/4885KMT2A 1275/4885 |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | FABP1, GPR119, FABP4 | ALDH1A1 119/4885KDM4E 376/4885KMT2A 1008/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | ALDH1A1 3438/4885KDM4E 647/4885KMT2A 315/4885 |
| US-20260085048-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ACSL3 | ALDH1A1 1031/4885KDM4E 1262/4885KMT2A 1477/4885 |
| US-20250223300-A1 | MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | EGFR, ERBB3, ERBB2 | ALDH1A1 3526/4885KDM4E 2994/4885KMT2A 3995/4885 |
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | ALDH1A1 2174/4885KDM4E 2469/4885KMT2A 3899/4885 |
| US-20250250264-A1 | KIF18A INHIBITOR AND USE THEREOF | KIF18A, KIF18B, KIF15 | ALDH1A1 1345/4885KDM4E 1075/4885KMT2A 141/4885 |
| US-12441689-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, ADSS2, GLS2 | ALDH1A1 347/4885KDM4E 1691/4885KMT2A 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.